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Conclusion. Losartan decreased serum uric acid and in-Safety of losartan in hypertensive patients with thiazide-induced
creased uric acid excretion without increasing urinary dihydro-hyperuricemia.
gen urate, the primary risk factor for acute urate nephropathy,Background. Losartan, an angiotensin II receptor antago-
during 21 days of dosing in hypertensive patients with thiazide-nist, has been shown to decrease serum uric acid and to increase
induced hyperuricemia.urinary excretion of uric acid.
Methods. To determine if this effect can increase the risk
of acute urate nephropathy, 63 hypertensive patients with thia-
zide-induced asymptomatic hyperuricemia (serum uric acid 7.0
Losartan represents a new class of blood pressure-to 12.0 mg/dl) were randomized double-blind to losartan 50
lowering drugs that act by blocking angiotensin II recep-mg every day (q.d.), losartan 50 mg plus hydrochlorothiazide
(HCTZ) 50 mg q.d., HCTZ 50 mg q.d., or placebo for three tors [1]. Losartan also increases the excretion of urate
weeks. To potentiate the risk of crystal formation, patients after dosing [2]. The mechanism of uricosuria is not fully
received a 2 g/kg protein diet one day prior to each clinic visit
understood but appears to be a unique effect of theon days 0 (baseline), 1, 7, and 21.
parent compound (not the metabolite) on urate reab-Results. Adverse events typically associated with acute urate
nephropathy, for example, flank pain, hematuria, or increased sorption in the renal proximal tubule [3]. If urine volume
blood urea nitrogen/creatinine, were not reported. Uric acid does not increase, the urine concentration of total uric
excretion and urine pH increased four and six hours after acid will rise. This rise may increase urine supersatura-losartan on day 1 compared with day 0. Dihydrogen urate, the
tion (SS) with respect to undissociated uric acid and theprimary risk factor for crystal formation, decreased at four and
sodium, potassium, and ammonium salts of monohydro-six hours on day 1 compared with day 0 associated with the
concurrent rise in urine pH. Day 7 and 21 changes, compared gen urate [4] leading to crystal formation [5]. Undissoci-
with day 0, in uric acid excretion rate, urine pH, and dihydrogen ated uric acid is clinically the most relevant because uric
urate with losartan were comparable to day 1 results but were
acid crystals cause hematuria, flank pain, uric acid stones,not statistically significant. Serum uric acid was significantly
and in the most extreme case, acute uric acid nephropa-reduced after 21 days of therapy with losartan.
thy [5]. In fact, some uricosuric drugs, such as suprofen,
have produced these clinical manifestations [6]. Also,
uricosuria has been implicated as a cause of calcium
oxalate stones [7] through heterogeneous nucleation or
1 Losartan Uric Acid Study Group: Frederic Coe and Jason Umans depletion of macromolecular inhibitors of calcium oxa-
(University of Chicago, Chicago IL, USA), Charles Kaupke (University late crystallization [8].of California Irvine Medical Center, Orange, CA, USA), Barton Levine
In clinical studies and post-marketing reports, losartan(VA Medical Center, West Los Angeles, Los Angeles, CA, USA),
Thomas Marbury (Orlando Clinical Research Center, Orlando, FL, has not been reported to cause acute urate nephropathy
USA), F.G. McMahon (Clinical Research Center, New Orleans, LA, or kidney stones. However, because of its uricosuricUSA), Michael Smith (University Hospitals of Cleveland, Cleveland,
property, we have carried out this study to determineOH, USA), and Suzanne Swan (Hennepin County Medical Center,
Minneapolis, MN, USA). the effect of acute and chronic losartan dosing on SS of
urine with respect to uric acid and the monohydrogenKey words: hypertension, angiotensin II receptor antagonist, uric acid,
acute urate nephropathy, crystal formation. urate salts, as well as SS with respect to calcium oxalate
monohydrate (COM) and calcium monohydrogen phos-
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Fig. 1. Study design of this double-blind randomized,
parallel, placebo-controlled trial. Timed urine collec-
tions for stone profile analysis were done on days 0, 1,
7 and 21 in the clinic. To potentiate the risk of crystal
formation, all patients received a high-protein diet
(2 g/kg) one day prior to each clinic visit and were
placed on a 1500 ml fluid restriction during the visit.
METHODS (day 0) when serum and urine samples were taken every
two hours between 7 a.m. and 3 p.m. for electrolytes andHypothesis
stone risk profile analysis (hours 0, 2, 4 and 6 correspond-Our working hypothesis was that the drug will elevate
ing to 9 a.m., 11 a.m., 1 p.m., and 3 p.m., respectively).urine SS with uric acid and its monohydrogen urate salts
HCTZ and placebo for losartan were administered at 9and, therefore, the propensity for uric acid crystalliza-
a.m., and blood pressure was taken predose and everytions, and that such crystallizations might reduce urine
two hours thereafter until the patient was discharged at 3COM crystal growth inhibition. To test this hypothesis,
p.m.. Dipstick assessment for hematuria was done everywe compared urine SS values and COM crystal growth
two-hours postdose. At 3 p.m., the patient was dischargedinhibition of patients receiving losartan to those of paral-
and returned to the clinic at 7 a.m. the next morning.lel placebo controls. Many patients with high blood pres-
Treatment day 1 (Fig. 1) was an identical extendedsure receive thiazide diuretics as a primary or secondary
clinic visit. Single-blind HCTZ was discontinued, and pa-agent [9]. Because thiazides raise serum uric acid concen-
tients were randomized to either placebo, losartan 50 mg,tration [10] and therefore the potential magnitude of the
losartan 50 mg plus HCTZ 50 mg, or placebo daily.acute uricosuria one might expect from losartan, a pair
Patients continued study medication for three weeks andof patient groups pretreated with hydrochlorothiazide
had identical extended clinic visits on day 7 and day 21,(HCTZ) and given placebo or losartan were also studied.
with timed urine collections for electrolytes and stoneIn addition to the HCTZ therapy, all patients received
profiles.a high-protein diet, further potentiating the risk of stone
formation. Therefore, the resulting study was essentially Patients
a “stress test” for the kidney.
Sixty-three patients were entered into the study, 54
men (mean 6 sd, age 54 6 12) and 9 women (mean 6 sd,Study design
age 54 6 10) from seven centers (Table 1). Fifty-nineThe design was a double-blind, placebo-controlled
patients completed the study, and four discontinued onparallel study, with subjects entered randomly into one
day 1: one patient for hypotension in the losartan group,of four treatment groups: (a) losartan 50 mg daily, (b)
one patient for hypotension in the losartan/HCTZ group,losartan 50 mg/HCTZ 50 mg daily, (c) HCTZ 50 mg
one patient for providing insufficient urine at the speci-daily, and (d) placebo (Fig. 1). The duration of the study
fied collection times in the placebo group, and one pa-for each patient was approximately 6.5 weeks. At visit 1
tient, also in the placebo group, for personal reasons.of the baseline period (study day 221; Fig. 1), all patients
Before entering the baseline period, all subjects werediscontinued their antihypertensive medications; if they
required to have a history of diastolic blood pressurewere previously taking HCTZ, their usual dose was con-
between 90 and 105 mm Hg. By day 27, patients weretinued. Patients did not necessarily have asymptomatic
required to have asymptomatic hyperuricemia (serumhyperuricemia prior to entering the baseline period. An-
uric acid 7.0 to 12.0 mg/dl). All were judged to be other-giotensin-converting enzyme inhibitors were discon-
wise healthy based on pretreatment history and medicaltinued at least seven days before day 221. On day 14,
examination.all patients were started on single-blind HCTZ 50 mg and
Patients with any of the following were excluded fromlosartan placebo for two weeks. On day 27, a complete
the study: secondary hypertension, history of malignantqualifying laboratory evaluation was performed.
Eligible patients underwent a baseline day of tests hypertension, sitting systolic blood pressure .200 mm Hg,
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Table 1. Summary of patient baseline demographic characteristics
Characteristic Los Los/HCTZ HCTZ Placebo All
N 15 17 15 16 63
Sex—male % 67 88 87 100 86
Age (mean 6sd) 55611 5769 53614 53612 54 611
Age range 33–68 32–70 25–71 34–70 25–71
Caucasian % 67 65 60 56 62
Oriental % 0 6 0 6 3
Black % 33 24 40 31 32
Hispanic % 0 6 0 6 3
Years of hypertension (mean 6sd) 17610 968 1068 967 1169
Baseline systolic BP mm Hg 129 130 128 130 129
Baseline diastolic BP mm Hg 89 90 88 91 90
Abbreviations are: HCTZ, hydrochlorothiazide; Los, losartan.
history of cerebral vascular accidents or transient ische- calculated by an iterative computer algorithm EQUIL
[11]. Crystal growth inhibition was assayed on all samplesmic attacks within the past three years, myocardial in-
farction within the past year, or coronary angioplasty or [12]. All measurements were stored in a relational data-
base constructed for this purpose.coronary artery bypass surgery within the past six months,
angina pectoris, clinically significant arteriovenous (AV) Urine pH was measured on freshly voided specimens
at the end of each two-hour collection period by glassconduction disturbances, history of unexplained syn-
cope, and current or prior history of heart failure. Preg- electrode (Beckman Phi 72 pH Meter with a Beckman
pH electrode; Beckman, Palo Alto, CA, USA) with stir-nant or lactating women were excluded. Also excluded
were patients using any drug that could affect serum ring. All centers received standard instruction on the use
of the instrument. Blood samples for hematology anduric acid or uric acid excretion. All subjects signed an
informed consent form approved by the center’s institu- chemistry were analyzed by a central lab.
tional review board.
Data analysis
Diet Initial dosing. Comparisons between treatment groups
with respect to serum and urine uric acid levels, urineA dietitian instructed each patient to maintain a daily
diet of 2.5 mEq/kg sodium, 1.5 mEq/kg potassium, and uric acid excretion rates, and SS values for uric acid and
its monohydrogen urate salts, as well as urine COM crystal2 g/kg protein throughout the study. Patients were coun-
seled to avoid caffeine-containing beverages and any growth inhibition, were performed using repeated mea-
sures techniques. The between-treatment group analysesalcohol for 24 hours before the extended clinical visits.
Prior to each extended visit, patients were provided with were losartan versus placebo and losartan/HCTZ versus
HCTZ. Day 0 was baseline for the changes with initialcommercially available, defined-purine, prepacked fro-
zen meals for consumption at lunch and dinner. The dosing on day 1, as well as for subsequent changes in
serum uric acid. The parameter values were log trans-patient was kept fasting until 3 p.m. of the extended clinic
visit, and then he or she consumed another prepackaged formed prior to the analysis. The use of baseline values
as a covariate accounted for any differences (significantmeal and was also given one to consume at home be-
tween 7 and 8 p.m. Fluid intake was limited to 1500 ml or nonsignificant) that could have occurred because of
randomization. An analysis of covariance was used withduring the days of the extended clinical visits.
factors for treatment, hour, subject, baseline as a covari-
Laboratory measurements ate, and interaction between treatment and hour. Although
all pairwise comparisons are reported, the primary com-Complete hematology and chemistry were done at 7
parisons of interest were the responses of losartan 50 mga.m. each morning of the extended clinic visit. Serum
monotherapy versus placebo. An adjustment for multi-chemistry parameters for stone profile analysis included
plicity was done using the Bonferroni approach for thesodium, potassium, chloride, calcium, phosphate, magne-
comparisons of interest. The comparisons with observedsium, creatinine, and uric acid. Urine measurements in-
P # 0.0021 are considered statistically significant. Sig-cluded volume, pH, sodium, potassium, chloride, calcium,
phosphate, magnesium, creatinine, uric acid, oxalate, ci- nificant differences between treatment groups are re-
flected by the asterisks shown in the corresponding fig-trate, sulfate, and ammonia. SSs with respect to undisso-
ciated uric acid and the sodium, potassium, and ammo- ures. A 90% confidence interval was constructed about
the estimated treatment difference for each of the pa-nium monohydrogen urate salts, as well as with respect
to COM and calcium monohydrogen phosphate, were rameters using the results of the analysis of variance.
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Fig. 3. Serum uric acid at times zero, two, four, and six hours on day 1.Fig. 2. Urine uric acid excretion at times zero, two, four, and six hours
No significant changes between groups occurred on day 1. Symbols are:on day 1. Changes in urine uric acid were significant for losartan versus
(m) losartan, (h) losartan/HCTZ, (s) HCTZ, and (r) placebo. Barsplacebo (*P , 0.0021) at hours 4 and 6 and for losartan/hydrochlorothia-
represent 90% confidence limits.zide (HCTZ) versus HCTZ (1P , 0.0021) at six hours. Symbols are:
(m) losartan, (h) losartan/HCTZ, (s) HCTZ, and (r) placebo. Bars
represent 90% confidence limits.
nificant at four hours in the losartan group compared
with the placebo group. Despite uricosuria, serum uric
The antilogs of the upper and lower limit then were acid levels did not fall significantly in any group on day 1
calculated to obtain the confidence interval for the ratio (Fig. 3).
of the geometric means. Individual treatments by hour
Urine pH rose in both losartan groups on day 1 com-
geometric means were reported and plotted. A similar
pared with day 0. The increase from baseline was signifi-
approach was used to address the comparisons within
cant at hours 4 and 6 for losartan versus placebo, but
each treatment group. From a different point of view,
not for losartan/HCTZ versus HCTZ alone (Fig. 4). Thisthe within-treatment analysis provides information about
was because pH rose significantly in the HCTZ alonethe behavior of a treatment group during the trial, com-
group, whereas urine pH remained low in the placeboparing the treatment effect from day 0 to days 1, 7, and
group, which serves as the contrast for losartan alone.21. The parameter values were log transformed prior to
The urine concentration of dihydrogen urate decreasedthe analysis. An analysis of variance was used with fac-
significantly on day 1 compared with day 0 at hours 4tors for day, hour, subject, and interaction between day
and 6 within all the groups except placebo. This decreaseand hour. Significant differences within a treatment
in dihydrogen urate concentration was significant atgroup are reflected by the confidence limits that do not
hours 4 and 6 for losartan compared with placebo (Fig. 5).overlap the value of 1, as shown in the corresponding
Repeated dosing with losartan resulted in a gradualfigures.
waning of uricosuric and pH effects. When comparingSubsequent dosing. We questioned if the initial dosing
hour 4 to hour 0 on day 7, both effects were significanteffects on urine pH and uric acid excretion rate would
(P , 0.05) within the losartan group but of less magni-recur after repeated dosing on days 7 and 21. To evaluate
tude (Figs. 6 and 7). On day 21, uric acid excretion didthis question, predose and four-hour postdose measure-
not rise above baseline for that day with dosing.ments were compared.
Because higher urine pH increases the urine concen-
tration of monohydrogen urate, just as it decreases con-
RESULTS centrations of dihydrogen urate, sodium hydrogen urate
concentration and its SS values rose on day 21 comparedThe four patient groups were well matched with re-
with day 0 (not displayed). Also, the potassium hydrogenspect to demographic variables (Table 1). There were
urate concentration rose significantly at four hours. Am-two statistical analyses performed on the data: within
monium urate concentrations did not show a marked in-treatment groups at each relevant time point for day 1,
crease. Although urate salts have been reported to absorb7, and 21 and between each treatment group over the
urine inhibitors, we found no change in COM crystalcourse of the trial for days 1, 7, and 21. Following the
growth inhibition. Despite changes in pH, we found noinitial dose of losartan, urine uric acid excretion signifi-
significant increases in COM or Br SS. Other urine pa-cantly rose within each group at hours 4 and 6 as ex-
rameters that did not show a clinically important changepected, whether or not patients were taking HCTZ. The
on day 21 compared with baseline (day 0, hour 0) in-increase was highly significant for losartan compared
cluded ammonium, ammonium monohydrogen urate, andwith placebo and losartan/HCTZ compared with HCTZ
at six hours after dosing (Fig. 2). It was also highly sig- its SS, oxalate, phosphate, potassium, potassium excretion
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Fig. 4. Urine pH at times zero, two, four, and six hours on day 1.
Changes in urine pH were significant for losartan versus placebo (*P ,
0.0021) at four and six hours. Symbols are: (m) losartan, (h) losartan/
Fig. 5. Dihydrogen urate SS (uric acid supersaturation) at times zero,HCTZ, (s) HCTZ, and (r) placebo. Bars represent 90% confidence
two, four, and six hours on day 1. Decreases in dihydrogen urate SSlimits.
were significant for losartan versus placebo (*P , 0.0021) at hours 4
and 6. Symbols are: (m) losartan, (h) losartan/HCTZ, (s) HCTZ, and
(r) placebo. Bars represent 90% confidence limits.
Fig. 6. Uric acid excretion rate response to
subsequent dosing with losartan. Hours 0 and
4 measurements for each patient are shown.
Changes at hour 4 were significant (*P , 0.05,
adjusted for placebo) on days 1 and 7 but not
on day 21. Symbols are: (m) losartan and (s)
placebo.
rate, potassium urate SS, sodium hydrogen urate, sulfate, DISCUSSION
calcium, calcium monohydrogen phosphate, calcium ox- Losartan reduces serum uric acid and raises the urine
alate and its SS, calcium oxalate inhibition, citrate, creati- concentration of uric acid, but unlike any other drug
nine, creatinine clearance, magnesium, and chloride. with uricosuric potential, losartan simultaneously raises
Serum uric acid gradually fell in the losartan groups urine pH so that undissociated uric acid SS fails to rise.
(Fig. 8). However, serum uric acid also fell in the placebo This is the expected effect of a rising urine pH. The
group, as a likely reflection of discontinuation of HCTZ fall in undissociated uric acid SS despite uricosuria with
usage. However, the fall with losartan alone was more losartan illustrates that the effects of the drug on urine
marked than in the placebo alone group, as was the pH, coupled with the logarithmic relationship between
fall in the losartan/HCTZ group compared with HCTZ urine pH and the proportion of urate species in the
alone. The effect of losartan on reduction of serum uric dihydrogen urate form, counterbalance the uricosuria
acid was maintained after three weeks of therapy. No entirely. As a result, stone risk from acute uric acid
patient experienced flank pain, hematuria, or gross crys- (dihydrogen urate) nephropathy falls when losartan is
first taken. For this reason, losartan appears to have notalluria during losartan dosing.
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Fig. 7. Urine pH response to subsequent dos-
ing. Hours 0 and 4 measurements for each sub-
ject are shown. Changes at hour 4 were signifi-
cant (*P , 0.05, adjusted for placebo) on days
1 and 7 but not on day 21. Symbols are (m)
losartan and (s) placebo.
type 2 (AT-2) receptor subtypes [17]. These effects are
consistent with the well-established effect of Ang II in
stimulating proximal tubule bicarbonate reabsorption
[18, 19]. Luminal losartan inhibits the effects of Ang II
to stimulate bicarbonate reabsorption in the early and
late rat distal tubule [20]. In whole animal studies, losar-
tan increased urine sodium but not chloride excretion
during sodium chloride depletion, an effect best ex-
plained by reduced renal tubule bicarbonate reabsorp-
tion [21]. In rats with 5/6 nephrectomy remnant kidneys,
losartan given either intravenously or placed in the distal
tubule lumen greatly reduced bicarbonate reabsorption
Fig. 8. Serum uric acid response to subsequent dosing with losartan. [22]. Given this background, our findings are consistent
Serum uric acid fell significantly (**P , 0.001) in the losartan group with all prior work, in that the lack of a rise in uric acidversus placebo by day 7 and remained significantly (*P , 0.05) de-
SS with losartan is a predictable consequence of thecreased on day 21. Serum uric also fell significantly (*P , 0.01) in the
losartan/HCTZ group versus the HCTZ group but was not significant effects of the drug on bicarbonate reabsorption.
at day 21. Symbols are: (m) losartan, (h) losartan/HCTZ, (s) HCTZ, Because urine pH rises, the uricosuria from losartanand (r) placebo. Bars represent 90% confidence limits.
raises urine SS with respect to the salts of monohydrogen
urate, even though SS with respect to uric acid alone
falls. In principle, these salts could cause stones and
potential for fostering the crystallization of uric acid and crystalluria. Ammonium acid urate stones are well docu-
should not lead to uric acid crystalluria with resultant mented in laxative abuse [23], colectomy, and malabsorp-
risk of stones or acute uric acid nephropathy. tion syndromes, as well as in potassium depletion [23–25].
Prior investigators have demonstrated the effect of Sodium monohydrogen urate stones are extremely rare
blockade of the renin-angiotensin-aldosterone system [26]. However, compared with undissociated uric acid,
with angiotensin-converting enzyme (ACE) inhibitors these salts have little clinical stone potential in humans.
or angiotensin II (Ang II) antagonists on bicarbonate Moreover, despite the theoretical possibility that they
reabsorption [13]. Captopril increased urine pH in bicar- absorb and reduce urine levels of COM crystallization
bonate-infused rats [14]. Saralasin reduced rat proximal inhibitors [8], we found no reduction in COM growth
tubule bicarbonate reabsorption [15]. In rats, losartan inhibition. COM and Br SS themselves showed no consis-
markedly reduced bicarbonate reabsorption in the S1 tent pattern of change with losartan.
segment of the proximal tubule [16]. Reduction of bicar- Serum uric acid decreased in both the losartan group
bonate reabsorption occurs in rat proximal tubule with and the placebo group by day 7. The decrease in serum
uric acid is partially an expected result of discontinuingantagonists of both the Ang II type 1 (AT-1) and Ang II
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8. Coe FL, Parks JH: New insights into the pathophysiology andHCTZ at the time of randomization. However, the de-
treatment of nephrolithiasis: New research venues. J Bone Miner
crease in serum uric acid with losartan was significantly Res 12:522–533, 1997
9. Kaplan NM: Treatment of hypertension: Drug therapy, in Clinicalmore than with placebo on day 7. Interestingly, by day
Hypertension, Baltimore, Williams & Wilkins, 1994, p 19121, serum uric acid remained significantly lower with
10. Weiner IM: Diuretics and other agents employed in the mobiliza-
losartan compared with placebo in spite of a less pro- tion of edema fluid, in Goodman and Gilman’s The Pharmacologi-
cal Basis of Therapeutics, edited by Gilman AG, Rall TW, Niesnounced uricosuric effect observed at the end of the
AS, Taylor P, New York, McGraw-Hill, 1993, p 713study. This sustained reduction may represent a new
11. Finlayson B: Calcium stones: Some physical and clinical aspects,
steady state for serum uric acid. in Calcium Metabolism In Renal Failure And Nephrolithiasis, ed-
ited by David DS, New York, John Wiley & Sons, 1977, p 337Overall, these results do not support the hypothesis
12. Nakagaw AY, Abram V, Kezdy FJ, Kaiser ET, Coe FL: Purifica-of increased undissociated uric acid concentrations in
tion and characterization of the principal inhibitor of calcium oxa-
urine from the uricosuric effects of losartan. Instead, late monohydrate crystal growth in human urine. J Biol Chem
258:12594–12600, 1983because of its dual effects to increase uric acid and bicar-
13. Xie MH, Liu FY, Wong P, Timmermans PB, Cogan M: Proximalbonate excretion together, the drug essentially cancels
nephron and renal effects of DuP753, a nonpeptide angiotensin
the effects of uricosuria on uric acid SS by raising urine II receptor antagonist. Kidney Int 38:473–479, 1990
14. Brukman J, Murray RD, Churchill PC, Scicli AG, CarreteropH. With chronic dosing, the uricosuric and bicarbonatu-
OA: Effect of urinary alkalinization on the intrarenal formationria effects wane, making the risk of uric acid crystal
of kinins. Am J Physiol 249:F827–F831, 1995
formation even less likely. 15. Liu FY, Cogan MG: Role of angiotensin II in glomerulotubular
balance. Am J Physiol 259:F72–F79, 1990
16. Cogan MG, Xie MH, Liu FY, Wong P, Timmermans PB: Effects ofACKNOWLEDGMENTS
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